Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. VYNE Therapeutics Inc.
  6. News
  7. Summary
    VYNE   US92941V2097

VYNE THERAPEUTICS INC.

(VYNE)
  Report
Real-time Estimate Cboe BZX  -  10:20 2022-07-06 am EDT
0.4470 USD   -1.54%
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis - Form 8-K
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/12/2022 | 04:22pm EDT
share with twitter
share with LinkedIn
share with facebook

VYNE Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.178 million compared to USD 0.23 million a year ago. Net income was USD 4.67 million compared to net loss of USD 20.55 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.22 a year ago. Basic earnings per share was USD 0.08 compared to basic loss per share of USD 0.42 a year ago.


© S&P Capital IQ 2022
All news about VYNE THERAPEUTICS INC.
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of ..
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
06/17VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of..
AQ
06/17VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatm..
CI
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,78x
Yield 2022 -
Capitalization 26,3 M 26,3 M -
Capi. / Sales 2022 60,7x
Capi. / Sales 2023 105x
Nbr of Employees 28
Free-Float 98,5%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,45 $
Average target price 6,00 $
Spread / Average Target 1 222%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-55.49%26
JOHNSON & JOHNSON4.94%468 758
ELI LILLY AND COMPANY17.55%294 514
PFIZER, INC.-11.41%289 747
ABBVIE INC.13.69%272 011
ROCHE HOLDING AG-15.85%269 131